Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/evaluating-cancer-drugs-in-patients-with-central-nervous-system-i9g406fZ42
References (4)
-
10.1001/jamaoncol.2021.0180
-
L. Nayak, E. Lee, P. Wen (2012)
Epidemiology of Brain MetastasesCurrent Oncology Reports, 14
-
S. Peters, D. Camidge, A. Shaw, S. Gadgeel, J. Ahn, Dong-Wan Kim, S. Ou, M. Pérol, R. Dziadziuszko, R. Rosell, A. Zeaiter, E. Mitry, S. Golding, B. Balas, J. Noé, P. Morcos, T. Mok (2017)
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 377
-
R. Murthy, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. Hurvitz, N. Lin, V. Borges, V. Abramson, C. Anders, P. Bedard, Mafalda Oliveira, E. Jakobsen, T. Bachelot, S. Shachar, V. Müller, S. Braga, F. Duhoux, R. Greil, D. Cameron, L. Carey, G. Curigliano, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, M. Palanca-Wessels, L. Walker, W. Feng, E. Winer (2019)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.The New England journal of medicine
- Publisher
- American Medical Association
- Copyright
- Copyright 2021 American Medical Association. All Rights Reserved.
- ISSN
- 2374-2437
- eISSN
- 2374-2445
- DOI
- 10.1001/jamaoncol.2021.0180
- Publisher site
- See Article on Publisher Site
Abstract
This Viewpoint discusses the challenges and potential benefits of including patients with active central nerve system metastases in clinical trials that evaluate cancer drugs.
Journal
JAMA Oncology – American Medical Association
Published: Aug 15, 2021